Emerging Diet Mixed tiers

Ginkgo Biloba

Summary

Ginkgo biloba has modest evidence for improving circulation and some cognitive symptoms in older adults, but large clinical trials failed to show it prevents dementia. The supplement works by improving blood flow and has real pharmacological effects, including a meaningful bleeding risk when combined with blood thinners. While it's not the brain-boosting miracle it's often marketed as, ginkgo does have legitimate uses for circulation problems and may help with existing cognitive symptoms—just not prevention of cognitive decline.

The evidence is moderate overall, with the largest and most definitive study (over 3,000 people followed for 6+ years) showing no benefit for dementia prevention. However, smaller studies suggest it may help with symptoms in people who already have cognitive impairment, and there's good evidence for circulation benefits.

Why Emerging

Tier 3 because mechanism is real (flavonoid glycosides + terpene lactones improve circulation via vasodilation and reduced viscosity, plus PAF antagonism explaining both circulation benefit and bleeding risk) but the headline claim — dementia prevention — was definitively disconfirmed. The GEM trial (n=3,069 adults 75+, 6+ years, EGb 761 240mg/day) found no dementia incidence reduction, ending the prevention claim. Tier 2 specifically for established clinical indications: Cochrane reviews support intermittent claudication benefit; smaller meta-analyses show symptom-management effects in existing cognitive impairment comparable to cholinesterase inhibitors. Bleeding risk with anticoagulants is pharmacologically predictable and clinically meaningful. Not Tier 2 overall because product quality varies (only standardised EGb 761 has the evidence, unstandardised products may contain allergenic ginkgolic acids), and the mainstream supplement marketing oversells beyond the actual indications.

Tier 2 for established indications (claudication, existing cognitive impairment); Tier 3 for general use

Practical takeaway

If you're considering ginkgo, it's most appropriate for circulation issues like cold extremities or leg pain from poor blood flow, or as support for existing mild cognitive symptoms (not prevention). Use only standardized extracts (120-240mg daily, standardized to 24% flavonoid glycosides). However, avoid ginkgo entirely if you take blood thinners, NSAIDs, or have surgery planned, as it genuinely increases bleeding risk. Effects on circulation may appear within 2-4 weeks, while any cognitive benefits require 8-12 weeks to assess.

Key findings

Large clinical trial of 3,069 older adults found no reduction in dementia or Alzheimer's disease risk over 6+ years
Meta-analyses show modest improvements in cognitive symptoms and daily activities in people with existing dementia
Good evidence for improving peripheral circulation, particularly leg pain from poor blood flow (intermittent claudication)
Increases bleeding risk due to real pharmacological effects on blood clotting
Mixed evidence for tinnitus relief, with some people responding while others don't

Evidence detail

Ginkgo's active compounds include flavonoid glycosides and terpene lactones that improve blood flow through vasodilation and reduced blood viscosity. The supplement also blocks platelet-activating factor (PAF), which explains both its circulation benefits and bleeding risks. While the mechanism for improved blood flow is well-established, better cerebral circulation doesn't automatically translate to better cognition.

The most important study was the GEM trial, which followed 3,069 adults aged 75+ for over 6 years using the standardized EGb 761 extract at 240mg daily. This large, well-designed study found no significant reduction in dementia incidence, effectively ending claims about dementia prevention. However, smaller studies and meta-analyses suggest ginkgo may help manage symptoms in people who already have cognitive impairment, with effects sometimes comparable to prescription cholinesterase inhibitors.

For circulation, Cochrane reviews support modest benefits for intermittent claudication (leg pain from poor blood flow). The evidence for tinnitus is mixed, with some people experiencing relief while others see no benefit. The bleeding risk is real and pharmacologically predictable due to PAF antagonism, making drug interactions a serious concern.

Quality matters significantly with ginkgo products. Unstandardized leaf preparations may contain allergenic ginkgolic acids, so only standardized extracts should be used. The most-studied formulation is EGb 761, standardized to specific percentages of active compounds.

Sources (5)

Open in the Library: search, filter, every entry →